Department of Anatomy and Embryology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Department of Anatomy, Faculty of Medicine, Horus University, New Damietta 34517, Egypt.
Cells. 2022 Feb 21;11(4):746. doi: 10.3390/cells11040746.
Obesity causes renal changes (ORC), characterized by defective renal autophagy, lipogenesis, enhanced macrophage infiltration and apoptosis. We hypothesize that Dasatinib, a tyrosine kinase inhibitor, may ameliorate changes associated with obesity. We the mice with either Obesogenic diet (OD) or a standard basal diet. After 12 weeks, the mice received either vehicle or Dasatinib 4 mg/kg/d for an additional four weeks. We examined serum creatinine, urea, lipid profile and renal cortical mRNA expression for lipogenesis marker SREBP1, inflammatory macrophage marker iNOS and fibrosis markers; TGFβ and PDGFA genes; immunohistochemical (IHC) staining for CD68; inflammatory macrophage marker and ASMA; fibrosis marker, LC3 and SQSTM1/P62; autophagy markers and western blotting (WB) for caspase-3; and, as an apoptosis marker, LC3II/I and SQSTM1/P62 in addition to staining for H&E, PAS, Sirius red and histopathological scoring. Dasatinib attenuated renal cortical mRNA expression for SREBP1, iNOS, PDGFA and TGFβ and IHC staining for CD68, ASMA and SQSTM1/P62 and WB for caspase-3 and SQSTM1/P62, while elevating LC3 expression. Moreover, Dasatinib ameliorated ORC; glomerulosclerosis, glomerular expansion, tubular dilatation, vacuolation and casts; inflammatory cellular infiltration; and fibrosis. Dasatinib is a promising therapy for ORC by correcting autophagy impairment, attenuating lipogenesis, apoptosis and macrophage infiltration by inducing antifibrotic activity.
肥胖导致肾脏变化(ORC),其特征是肾自噬、脂生成、巨噬细胞浸润和凋亡受损。我们假设达沙替尼,一种酪氨酸激酶抑制剂,可能改善与肥胖相关的变化。我们用致肥胖饮食(OD)或标准基础饮食喂养小鼠。12 周后,小鼠接受载体或达沙替尼 4mg/kg/d 治疗,再持续 4 周。我们检测血清肌酐、尿素、脂质谱和肾皮质 mRNA 表达,以评估脂生成标志物 SREBP1、炎症性巨噬细胞标志物 iNOS 和纤维化标志物 TGFβ和 PDGFA 基因;免疫组织化学(IHC)染色用于 CD68;炎症性巨噬细胞标志物和 ASMA;纤维化标志物 LC3 和 SQSTM1/P62;自噬标志物和 WB 用于 caspase-3;以及作为凋亡标志物的 LC3II/I 和 SQSTM1/P62,此外还进行 H&E、PAS、天狼星红和组织病理学评分染色。达沙替尼可减弱肾皮质 SREBP1、iNOS、PDGFA 和 TGFβ 的 mRNA 表达以及 CD68、ASMA 和 SQSTM1/P62 的 IHC 染色和 WB 检测的 caspase-3 和 SQSTM1/P62,同时上调 LC3 的表达。此外,达沙替尼可改善 ORC;肾小球硬化、肾小球扩张、肾小管扩张、空泡化和管型;炎症细胞浸润;和纤维化。达沙替尼通过纠正自噬损伤、抑制脂生成、诱导抗纤维化活性来减少细胞凋亡和巨噬细胞浸润,为 ORC 提供了一种有前景的治疗方法。